(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.47%) $27.23
(0.41%) $924.25
(0.32%) $0.935
(0.80%) $11.04
(0.13%) $0.800
(-0.32%) $91.87
Live Chart Being Loaded With Signals
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide...
Stats | |
---|---|
Today's Volume | 5.41M |
Average Volume | 4.91M |
Market Cap | 1.20B |
EPS | HKD0 ( 2023-08-29 ) |
Last Dividend | HKD0.0100 ( 2021-06-16 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -3.73 |
ATR14 | HKD0.00400 (0.71%) |
Volume Correlation
VIVA Biotech Holdings Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
VIVA Biotech Holdings Correlation - Currency/Commodity
VIVA Biotech Holdings Financials
Annual | 2023 |
Revenue: | HKD2.16B |
Gross Profit: | HKD738.43M (34.26 %) |
EPS: | HKD-0.140 |
FY | 2023 |
Revenue: | HKD2.16B |
Gross Profit: | HKD738.43M (34.26 %) |
EPS: | HKD-0.140 |
FY | 2022 |
Revenue: | HKD2.38B |
Gross Profit: | HKD815.68M (34.28 %) |
EPS: | HKD-0.280 |
FY | 2021 |
Revenue: | HKD2.10B |
Gross Profit: | HKD650.98M (30.94 %) |
EPS: | HKD0.150 |
Financial Reports:
No articles found.
VIVA Biotech Holdings Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
First Dividend | HKD0.00500 | 2019-09-09 |
Last Dividend | HKD0.0100 | 2021-06-16 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 4 | -- |
Total Paid Out | HKD0.0470 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.76 | -- |
Div. Sustainability Score | 6.07 | |
Div.Growth Potential Score | 2.07 | |
Div. Directional Score | 4.07 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2362.HK | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
1349.HK | Ex Dividend Junior | 2023-06-05 | Annually | 0 | 0.00% | |
0393.HK | Ex Dividend Knight | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
6668.HK | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
1899.HK | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
0927.HK | Ex Dividend Knight | 2023-08-29 | Semi-Annually | 0 | 0.00% | |
0057.HK | Ex Dividend Knight | 2023-09-01 | Semi-Annually | 0 | 0.00% | |
2880.HK | Ex Dividend Junior | 2023-06-20 | Annually | 0 | 0.00% | |
1480.HK | Ex Dividend Junior | 2023-06-08 | Sporadic | 0 | 0.00% | |
0551.HK | Ex Dividend Junior | 2023-09-12 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0539 | 1.500 | -1.077 | -1.616 | [0 - 0.5] |
returnOnAssetsTTM | -0.0156 | 1.200 | -0.520 | -0.623 | [0 - 0.3] |
returnOnEquityTTM | -0.0317 | 1.500 | -1.463 | -2.19 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.324 | 0.800 | 8.38 | 6.70 | [1 - 3] |
quickRatioTTM | 0.941 | 0.800 | 9.17 | 7.34 | [0.8 - 2.5] |
cashRatioTTM | 0.675 | 1.500 | 7.36 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.255 | -1.500 | 5.75 | -8.62 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.370 | 2.00 | 9.88 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.252 | 2.00 | 9.87 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.515 | -1.500 | 7.94 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.343 | 1.000 | 7.62 | 7.62 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0894 | 1.000 | -0.212 | -0.212 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.167 | 1.000 | -0.183 | -0.183 | [0.2 - 2] |
assetTurnoverTTM | 0.289 | 0.800 | -1.404 | -1.124 | [0.5 - 2] |
Total Score | 6.07 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -3.83 | 1.000 | -0.487 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0317 | 2.50 | -0.941 | -2.19 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.252 | 2.00 | 9.92 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.370 | 2.00 | 9.88 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0301 | 1.500 | -3.53 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.147 | 1.000 | 8.82 | 0 | [0.1 - 0.5] |
Total Score | 2.07 |
VIVA Biotech Holdings
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure determination of protein, and SPR technology. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins. In addition, the company offers contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs) and intermediates; and trades in APIs, intermediates, and formulations, as well as equity for service. Further, it provides research service; laboratory rental services; and project management and bidding services, as well as sells compounds. The company was incorporated in 2008 and is headquartered in Shanghai, China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators